Weller, Michael ; Tabatabai, Ghazaleh ; Kästner, Bärbel ; Felsberg, Jörg ; Steinbach, Joachim P. ; Wick, Antje ; Schnell, Oliver ; Hau, Peter ; Herrlinger, Ulrich ; Sabel, Michael C. ; Wirsching, Hans-Georg ; Ketter, Ralf ; Bähr, Oliver ; Platten, Michael 
; Tonn, Jörg C. ; Schlegel, Uwe ; Marosi, Christine ; Goldbrunner, Roland ; Stupp, Roger ; Homicsko, Krisztian ; Pichler, Josef ; Nikkhah, Guido ; Meixensberger, Jürgen ; Vajkoczy, Peter ; Kollias, Spyros ; Hüsing, Johannes ; Reifenberger, Guido ; Wick, Wolfgang
; Tonn, Jörg C. ; Schlegel, Uwe ; Marosi, Christine ; Goldbrunner, Roland ; Stupp, Roger ; Homicsko, Krisztian ; Pichler, Josef ; Nikkhah, Guido ; Meixensberger, Jürgen ; Vajkoczy, Peter ; Kollias, Spyros ; Hüsing, Johannes ; Reifenberger, Guido ; Wick, Wolfgang MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Article
Weller, Michael, Tabatabai, Ghazaleh, Kästner, Bärbel, Felsberg, Jörg, Steinbach, Joachim P., Wick, Antje, Schnell, Oliver, Hau, Peter, Herrlinger, Ulrich, Sabel, Michael C., Wirsching, Hans-Georg, Ketter, Ralf, Bähr, Oliver, Platten, Michael, Tonn, Jörg C., Schlegel, Uwe, Marosi, Christine, Goldbrunner, Roland, Stupp, Roger, Homicsko, Krisztian, Pichler, Josef, Nikkhah, Guido, Meixensberger, Jürgen, Vajkoczy, Peter, Kollias, Spyros, Hüsing, Johannes, Reifenberger, Guido and Wick, Wolfgang
(2015)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Clinical Cancer Research 21 (9), pp. 2057-2064.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Clinical Cancer Research | ||||
| Publisher | AMER ASSOC CANCER RESEARCH | ||||
| Place of Publication | PHILADELPHIA | ||||
| Volume | 21 | ||||
| Number of Issue or Book Chapter | 9 | ||||
| Page Range | pp. 2057-2064 | ||||
| Date | 2015 | ||||
| Date of publication | 19 Dec 2024 07:34 | ||||
| Institutions | Medicine > Lehrstuhl für Neurologie | ||||
| Identification Number |
| ||||
| Keywords | NEWLY-DIAGNOSED GLIOBLASTOMA; PHASE-II TRIAL; SINGLE-AGENT BEVACIZUMAB; HIGH-GRADE GLIOMA; RECURRENT GLIOBLASTOMA; MALIGNANT GLIOMA; RANDOMIZED-TRIAL; CLINICAL-TRIAL; LOMUSTINE; RADIOTHERAPY; | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 60474 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric